Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Geoffrey T Gibney

Showing results (51-60 of 58) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 58 results.
Journal for Immunotherapy of Cancer|October 18, 2023
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of melanoma, version 3.0Anna C Pavlick, Charlotte E Ariyan, Elizabeth I Buchbinder, et al.
Oncoimmunology|December 15, 2018
Clinical characterization of colitis arising from anti-PD-1 based therapyDaniel Y Wang, Meghan J Mooradian, DaeWon Kim, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 8, 2014
Combined BRAF (Dabrafenib) and MEK inhibition (Trametinib) in patients with BRAFV600-mutant melanoma experiencing progression with single-agent BRAF inhibitorDouglas B Johnson, Keith T Flaherty, Jeffrey S Weber, et al.
Lancet (London, England)|January 21, 2024
Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b studyJeffrey S Weber, Matteo S Carlino, Adnan Khattak, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 5, 2022
First-in-Human Phase I/II ICONIC Trial of the ICOS Agonist Vopratelimab Alone and with Nivolumab: ICOS-High CD4 T-Cell Populations and Predictors of ResponseTimothy A Yap, Justin F Gainor, Margaret K Callahan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 8, 2021
The State of Melanoma: Emergent Challenges and OpportunitiesMichael B Atkins, Clara Curiel-Lewandrowski, David E Fisher, et al.
The British Journal of Dermatology|October 22, 2024
Combined programmed cell death protein 1 and cytotoxic T-lymphocyte associated protein 4 blockade in an international cohort of patients with acral lentiginous melanomaErin McGillivray, Karam Ashouri, Eftychia Chatziioannou, et al.
The New England Journal of Medicine|March 1, 2023
Neoadjuvant-Adjuvant or Adjuvant-Only Pembrolizumab in Advanced MelanomaSapna P Patel, Megan Othus, Yuanbin Chen, et al.
Pageof 6

Showing results (51-60 of 58) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 58 results.
Journal for Immunotherapy of Cancer|October 18, 2023
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of melanoma, version 3.0Anna C Pavlick, Charlotte E Ariyan, Elizabeth I Buchbinder, et al.
Oncoimmunology|December 15, 2018
Clinical characterization of colitis arising from anti-PD-1 based therapyDaniel Y Wang, Meghan J Mooradian, DaeWon Kim, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 8, 2014
Combined BRAF (Dabrafenib) and MEK inhibition (Trametinib) in patients with BRAFV600-mutant melanoma experiencing progression with single-agent BRAF inhibitorDouglas B Johnson, Keith T Flaherty, Jeffrey S Weber, et al.
Lancet (London, England)|January 21, 2024
Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b studyJeffrey S Weber, Matteo S Carlino, Adnan Khattak, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 5, 2022
First-in-Human Phase I/II ICONIC Trial of the ICOS Agonist Vopratelimab Alone and with Nivolumab: ICOS-High CD4 T-Cell Populations and Predictors of ResponseTimothy A Yap, Justin F Gainor, Margaret K Callahan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 8, 2021
The State of Melanoma: Emergent Challenges and OpportunitiesMichael B Atkins, Clara Curiel-Lewandrowski, David E Fisher, et al.
The British Journal of Dermatology|October 22, 2024
Combined programmed cell death protein 1 and cytotoxic T-lymphocyte associated protein 4 blockade in an international cohort of patients with acral lentiginous melanomaErin McGillivray, Karam Ashouri, Eftychia Chatziioannou, et al.
The New England Journal of Medicine|March 1, 2023
Neoadjuvant-Adjuvant or Adjuvant-Only Pembrolizumab in Advanced MelanomaSapna P Patel, Megan Othus, Yuanbin Chen, et al.
Pageof 6